Wells Fargo & Company MN trimmed its holdings in Cambrex Co. (NYSE:CBM) by 39.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 207,945 shares of the biotechnology company’s stock after selling 133,874 shares during the quarter. Wells Fargo & Company MN’s holdings in Cambrex were worth $10,874,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Aperio Group LLC raised its holdings in shares of Cambrex by 10.5% in the fourth quarter. Aperio Group LLC now owns 9,759 shares of the biotechnology company’s stock worth $468,000 after buying an additional 927 shares during the period. Stone Ridge Asset Management LLC purchased a new position in Cambrex during the 4th quarter worth $620,000. We Are One Seven LLC purchased a new position in Cambrex during the 4th quarter worth $320,000. MML Investors Services LLC purchased a new position in Cambrex during the 4th quarter worth $204,000. Finally, Teachers Advisors LLC increased its holdings in Cambrex by 3.8% during the 4th quarter. Teachers Advisors LLC now owns 369,203 shares of the biotechnology company’s stock worth $17,722,000 after purchasing an additional 13,557 shares during the period.
Cambrex opened at $46.65 on Monday, according to MarketBeat Ratings. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of 14.72, a PEG ratio of 1.14 and a beta of 2.27. Cambrex Co. has a 52 week low of $42.55 and a 52 week high of $62.30.
CBM has been the topic of several research reports. ValuEngine downgraded Cambrex from a “sell” rating to a “strong sell” rating in a report on Thursday, June 7th. Zacks Investment Research downgraded Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, May 10th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Cambrex presently has an average rating of “Hold” and a consensus target price of $60.00.
In other Cambrex news, CEO Steven M. Klosk sold 55,000 shares of the stock in a transaction on Monday, June 11th. The stock was sold at an average price of $45.64, for a total transaction of $2,510,200.00. Following the sale, the chief executive officer now owns 218,328 shares of the company’s stock, valued at approximately $9,964,489.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregory Sargen sold 67,500 shares of the stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $49.48, for a total value of $3,339,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 162,500 shares of company stock worth $7,837,700 over the last 90 days. 2.42% of the stock is currently owned by company insiders.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.